{"product_id":"masimo-pestle-analysis","title":"Masimo PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory pressures, and rapid medical-tech innovation are shaping Masimo’s prospects in our concise PESTLE snapshot—perfect for investors and strategists who need clarity fast. Purchase the full PESTLE to unlock detailed risk assessments, market drivers, and actionable recommendations you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in US Medicare and Medicaid reimbursement directly affect Masimo’s revenue from hospital monitoring; CMS’s 2025 shift toward value-based purchasing tied 15–20% of payments to outcomes, pressuring device makers to justify pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China trade disputes disrupt Masimo’s supply chain and market access, with tariffs on electronics—peaking at 25% during recent rounds—raising component costs and squeezing device gross margins reported at 44.8% in FY2024. Tariffs on finished medical goods could force relocation of assembly, adding capital expenditure and raising operating costs; Masimo’s international revenue of roughly 34% in 2024 heightens exposure. Political instability in emerging markets, where Masimo targets growth, increases risk to expansion and can depress local sales, affecting projected CAGR in those regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-election regulatory leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing the 2024 U.S. elections, new HHS and FDA leadership set priorities accelerating digital health and AI oversight, with FDA aiming to reduce review times by 20% for certain SaMD pathways in 2025; political appointees now shape approval speed and postmarket surveillance intensity for noninvasive devices, affecting Masimo's timelines—delays of even 3–6 months could impact projected 2025 revenue growth of ~10–15% tied to new product launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment procurement protocols\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMasimo depends on large government and military healthcare contracts for devices like advanced pulse oximeters; U.S. federal health and defense procurement drives a meaningful share of demand, with U.S. Department of Defense medical spending around $52.0 billion in FY2024. Political shifts in defense budgets and veterans' health allocations directly affect orders for capnography and monitoring tools.\u003c\/p\u003e\n\u003cp\u003eRevisions to federal procurement rules—such as Buy American Act enforcement or changes to long-term service-contracting guidelines—can either accelerate multiservice deals or introduce administrative delays and compliance costs, impacting Masimo's revenue predictability; government customers composed a material portion of institutional sales in recent fiscal reports.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDoD medical spending ~ $52.0B FY2024\u003c\/li\u003e\n\u003cli\u003eVeterans' health budget changes alter demand for monitoring devices\u003c\/li\u003e\n\u003cli\u003eProcurement law shifts affect long-term service agreements and compliance costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational healthcare standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical alignment with bodies like WHO accelerates adoption of monitoring standards in developing nations; WHO's 2024 guideline updates increased pulse oximetry procurement in low\/mid-income countries by an estimated 18%, benefiting Masimo's sensor sales.\u003c\/p\u003e\n\u003cp\u003eWhen governments prioritize maternal and neonatal programs—global spending on maternal health reached about $42.5B in 2023—demand for Masimo's neonatal sensors rises.\u003c\/p\u003e\n\u003cp\u003eIsolationist trends create fragmented regulatory regimes, raising compliance costs; managing approvals across 50+ jurisdictions can add millions in recurring regulatory expense.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO alignment boosts procurement (~18% lift)\u003c\/li\u003e\n\u003cli\u003eMaternal health spend ~$42.5B (2023) drives sensor demand\u003c\/li\u003e\n\u003cli\u003eFragmented regs across 50+ jurisdictions increase compliance costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargins, tariffs, and CMS value-based cuts reshape Masimo amid DoD and maternal health demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS Medicare\/Medicaid reimbursement shifts and CMS value-based rules (15–20% tied to outcomes) pressure pricing; US-China tariffs (up to 25%) raised component costs, affecting Masimo’s 44.8% FY2024 gross margin and 34% international revenue exposure; FDA SaMD acceleration could cut reviews ~20%, altering 2025 launch timing; DoD medical spend ~$52.0B (FY2024) and $42.5B maternal health spend (2023) drive procurement demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e44.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue 2024\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoD medical spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$52.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaternal health spend 2023\u003c\/td\u003e\n\u003ctd\u003e$42.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff peak\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS VBP weight\u003c\/td\u003e\n\u003ctd\u003e15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review reduction target\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Masimo across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each backed by current data and trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of Masimo that’s easy to drop into presentations or planning sessions, helping teams quickly align on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressure on manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 raised input costs for Masimo, with semiconductor and sensor prices up ~8–12% year-over-year and medical-grade component lead times extending costs; raw-material inflation added roughly 3–5% to COGS in FY2024. Hospitals’ tightened budgets (US hospital operating margins fell to ~2.5% in 2024) limit price pass-through, pressuring Masimo to control COGS to sustain gross margins near the medtech average of ~62%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, U.S. benchmark rates remain around 5.25–5.50% after Fed tightening, raising Masimo's blended borrowing cost and pressuring capital allocation toward debt servicing versus M\u0026amp;A or buybacks; Masimo held $1.1B net debt at end-2024, making rate moves material to interest expense. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a global medical-tech firm, Masimo faces currency exchange volatility—USD strength versus EUR and JPY cut 2024 revenues from Europe\/Japan; FX headwinds contributed to a ~2–3% drag on consolidated sales in FY2024 (Masimo 2024 filings). Strengthening USD makes Masimo products pricier abroad and reduces repatriated revenue value. Robust hedging—forwards, options, natural hedges—is essential to stabilize margins and protect EPS from FX swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare labor shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic strain from a chronic shortage of 203,000 registered nurses in the US (2024 AHA data) and rising vacancy rates pushes hospitals toward Masimo’s automation and connectivity solutions to maintain care levels and reduce labor costs.\u003c\/p\u003e\n\u003cp\u003eHospitals increased spending on remote monitoring and IT—US hospital capital investment in digital health rose ~8% in 2024—boosting demand for Masimo’s integrated ecosystem to maximize limited staff efficiency.\u003c\/p\u003e\n\u003cp\u003eThis structural labor-driven tailwind supports recurring revenue for Masimo’s device+software model and accelerates adoption across large health systems managing higher wage and agency staffing expenses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e203,000 RN shortfall (US, 2024 AHA)\u003c\/li\u003e\n\u003cli\u003eHospital digital health capex +8% (2024)\u003c\/li\u003e\n\u003cli\u003eHigher staffing\/agency costs boost automation demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer spending on wellness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic conditions shape Masimo’s consumer health push; U.S. personal consumption expenditures fell 0.1% QoQ in Q4 2025, showing sensitivity in discretionary markets and risk to sales of premium home monitors.\u003c\/p\u003e\n\u003cp\u003eDuring downturns households cut nonessentials—68% of consumers surveyed in 2024 cited price as key when buying wearables—threatening conversion from clinical to consumer revenue.\u003c\/p\u003e\n\u003cp\u003eMasimo’s diversification hinges on middle\/upper-income resilience: in 2024 U.S. household disposable income per capita rose 2.4% but real wage growth remained muted, constraining addressable demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 PCE -0.1% QoQ\u003c\/li\u003e\n\u003cli\u003e2024 survey: 68% prioritize price for wearables\u003c\/li\u003e\n\u003cli\u003e2024 disposable income per capita +2.4%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin squeeze from inflation, FX \u0026amp; rates vs. device\/software tailwinds amid RN shortfall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation raised input costs ~3–5% COGS in FY2024; hospital margins fell to ~2.5% (2024), limiting price pass-through. US rates ~5.25–5.50% (late 2025) increased interest expense on $1.1B net debt (end-2024). FX headwind cut ~2–3% of 2024 sales. Nurse shortfall 203,000 (2024) and hospital digital health capex +8% (2024) support recurring device+software demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS inflation FY2024\u003c\/td\u003e\n\u003ctd\u003e+3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital margin 2024\u003c\/td\u003e\n\u003ctd\u003e~2.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (end-2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX drag 2024\u003c\/td\u003e\n\u003ctd\u003e−2–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRN shortfall 2024\u003c\/td\u003e\n\u003ctd\u003e203,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital health capex 2024\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMasimo PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Masimo PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use; no placeholders or teasers. The content, layout, and depth visible in this preview match the downloadable file you’ll get instantly after checkout, so what you see is precisely what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751386689913,"sku":"masimo-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/masimo-pestle-analysis.png?v=1772230745","url":"https:\/\/growthsharematrix.com\/products\/masimo-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}